← Leaderboards
Leor S Weinberger
University Of California, San Diego
$28,674,235
Attributed
$31,233,026
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5M · FY2008–25$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,233,026 · 12
By mechanism
DP1$10,468,662 · 2
R01$9,499,721 · 3
R37$6,200,336 · 1
DP2$2,317,500 · 1
R56$975,928 · 1
K25$764,108 · 1
Top collaborators
- Robert Rodick3 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- Omar Sultan Akbari$9,379,133
- Valentino Matteo Gantz$2,172,932
- Kimberly L Cooper$4,885,064
- Steffanie A Strathdee$53,933,577
- Shelley M Lawrence$2,876,915
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsViralVirusBaseMolecularIn VivoEngineeringSafetyPathogenGenesInfectionEvolutionMathematical ModelResistanceGene ExpressionTransmission ProcessVariantNoiseVirus DiseasesNonhuman PrimateFeedbackAnimalsAcquired Immunodeficiency SyndromeGenetic
Grant awards (46)
Modulating Stochastic Gene Expression for Cell-fate Control and Therapeutics$1,927,847
R37 · FY2025 · AI · contact PI
Targeting Feedback Circuitry for Antiviral Therapy$1,510,374
R01 · FY2025 · AI · contact PI
Targeting Feedback Circuitry for Antiviral Therapy$944,989
R01 · FY2024 · AI · contact PI
Modulating Stochastic Gene Expression for Cell-fate Control and Therapeutics$905,866
R37 · FY2024 · AI · contact PI
A Gene Drive Therapy for HIV: Single-Administration Intervention for High-RiskGroups$716,839
DP1 · FY2024 · DA · contact PI
Modulating Stochastic Gene Expression for Cell-fate Control and Therapeutics$471,273
R37 · FY2024 · AI · contact PI
A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups$228,161
DP1 · FY2024 · DA · contact PI
Modulating Stochastic Gene Expression for Cell-fate Control and Therapeutics$95,634
R37 · FY2024 · AI · contact PI
Autonomously deploying, co-evolving SARS-CoV-2 antiviral: a new paradigm for pandemic prevention$1,997,089
R01 · FY2023 · AI
A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups$945,000
DP1 · FY2023 · DA · contact PI
Modulating Stochastic Gene Expression for Cell-fate Control and Therapeutics$918,446
R37 · FY2023 · AI · contact PI
Development of a first-in-class antiviral to address CMV drug resistance in immunocompromised patients$300,000
R42 · FY2023 · AI
A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups$187,110
DP1 · FY2023 · DA · contact PI
A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups$945,000
DP1 · FY2022 · DA · contact PI
Modulating Stochastic Gene Expression for Cell-fate Control and Therapeutics$918,446
R37 · FY2022 · AI · contact PI
A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups$189,000
DP1 · FY2022 · DA · contact PI
A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups$107,276
DP1 · FY2022 · DA · contact PI
Autonomously deploying, co-evolving SARS-CoV-2 antiviral: a new paradigm for pandemic prevention$2,820,494
R01 · FY2021 · AI
Modulating Stochastic Gene Expression for Cell-fate Control and Therapeutics$962,824
R37 · FY2021 · AI · contact PI
A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups$945,000
DP1 · FY2021 · DA · contact PI
A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups$189,000
DP1 · FY2021 · DA · contact PI
A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups$107,276
DP1 · FY2021 · DA · contact PI
A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups$945,000
DP1 · FY2020 · DA · contact PI
A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups$189,000
DP1 · FY2020 · DA · contact PI
Development of a Technology Platform for Engineering Single-Administration HIV Therapeutics$975,928
R56 · FY2019 · AI · contact PI
Stochastic Gene Expression in Retroviral Latency$440,195
R01 · FY2018 · AI · contact PI
Evolvable 'Resistance-Proof' Therapies$955,000
DP1 · FY2017 · DE · contact PI
Stochastic Gene Expression in Retroviral Latency$440,195
R01 · FY2017 · AI · contact PI
Evolvable 'Resistance-Proof' Therapies$955,000
DP1 · FY2016 · DE · contact PI
Stochastic Gene Expression in Retroviral Latency$440,195
R01 · FY2016 · AI · contact PI
Evolvable 'Resistance-Proof' Therapies$955,000
DP1 · FY2015 · DE · contact PI
Stochastic Gene Expression in Retroviral Latency$440,195
R01 · FY2015 · AI · contact PI
Experiment & Theory to Test an Evolutionary Fitness Role for Lentiviral Latency$241,477
R21 · FY2015 · AI · contact PI
Evolvable 'Resistance-Proof' Therapies$955,000
DP1 · FY2014 · DE · contact PI
Stochastic Gene Expression in Retroviral Latency$465,995
R01 · FY2014 · AI · contact PI
Experiment & Theory to Test an Evolutionary Fitness Role for Lentiviral Latency$298,122
R21 · FY2014 · AI · contact PI
Evolvable 'Resistance-Proof' Therapies$955,000
DP1 · FY2013 · DE · contact PI
2.3 Microfluidics to probe regulation & treatment of HIV latency in single cells$167,172
U19 · FY2012 · AI · contact PI
How Feedback Circuitry Drives Phenotype Switching in a Human Herpesvirus$137,779
K25 · FY2012 · GM · contact PI
How Feedback Circuitry Drives Phenotype Switching in a Human Herpesvirus$137,779
K25 · FY2011 · GM · contact PI
How Feedback Circuitry Drives Phenotype Switching in a Human Herpesvirus$137,779
K25 · FY2010 · GM · contact PI
Developing Transmissible Antivirals by Exploiting Gene-Expression Circuitry$1,465,000
DP2 · FY2009 · OD · contact PI
Developing Transmissible Antivirals by Exploiting Gene-Expression Circuitry$852,500
DP2 · FY2009 · OD · contact PI
How Feedback Circuitry Drives Phenotype Switching in a Human Herpesvirus$126,571
K25 · FY2009 · GM · contact PI
How Feedback Circuitry Drives Phenotype Switching in a Human Herpesvirus$100,000
K25 · FY2009 · GM · contact PI
How Feedback Circuitry Drives Phenotype Switching in a Human Herpesvirus$124,200
K25 · FY2008 · GM · contact PI